How can we help?


Bioneer assists clients in the pre-clinical and early clinical phases with production of recombinant proteins in a variety of mammalian cell systems, with access to existing or development of novel functional assays based upon mammalian cells as well as general technology development, e.g. bioreactor evaluation, biobanking, and cell handling. In fact, we can support our clients in the entire process of bringing a novel biologic compound from the laboratory through pre-clinical evaluation for functionality and safety.


Bioneer offers evaluation of compounds using mainly three cell systems 1) Primary dendritic cells (human and murine) 2) Peripheral blood mononuclear cells (PBMCs) and 3) cell line based models. We provide services in our model systems in the discovery process (mainly evaluation of mechanism of action and immune modulation and suppression of specific inflammatory responses) as well as activities involved in the development process (mainly evaluation of safety of IV administered drugs, and assessment of potency).


Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.


Turning an active compound into a drug product

Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.

Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark.


Bioneer offers a range of services related to the identification, validation and documentation of disease relevant biomarkers and drug targets. These services comprise a toolbox of molecular methods that will facilitate the pre-clinical development of both biomarkers, drug-targets and active compounds, which will be useful in diagnostic, prognostic, and therapeutic contexts, and, furthermore, serve as effective means to optimize clinical trial designs.


The Dynamic Gastric Model is the first true "dynamic" in-vitro model of the human stomach that fully replicates the complex biochemical conditions and the array of gastric forces crucial for the prediction of oral pharmaceuticals and food products


Bioneer is part of new groundbreaking project granted 25 MDKK by Innovation Fund Denmark

Rigshospitalet, Cook Regentec, Terumo BCT and Bioneer are partners in a novel five-year innovation project aiming at improving stem cell treatment for patients with chronic heart disease.

Read more
Bioneer is now a certified provider of RNAscope® Assays for in situ hybridization
Bioneer is happy to announce that it has become a certified provider of RNAscope® assays, which widens the panel of analyses provided in the field of mRNA and lncRNA detection considerably.
Read more
Søren Carlsen joins Bioneer as Director of the Board

Bioneer welcomes Søren Carlsen as new Director of the Board. Thereby the Board includes an experienced and well-recognized person, who knows the Danish Life Science industry inside out.

Read more

Meet us at:

Companion Diagnostics, workshop, January 31, Copenhagen

Companion diagnostics is receiving a lot of attention these years because reimbursement is and will become highly dependent on treatment performance of a drug "in daily use".  Learn more about the current status of the area at the workshop.  

Read more
Medicon Valley Alliance Oncology Network meeting January 30th 2017

Bioneer is active in the biomarker field and is heading the Danish Biomarker Network. We are looking forward to meeting potential collaborators in the field of oncology.

Read more
Other places to meet us